Production of functional myeloid cells from CD34‐selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system
- 1 January 1994
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 12 (6) , 626-637
- https://doi.org/10.1002/stem.5530120610
Abstract
There is increasing clinical interest focused on ex vivo manipulation and expansion of hematopoietic cells. In this study, we demonstrate that a simple combination of growth factors can expand progenitors to yield functional myeloid cells. Furthermore, this system can produce mature, functionally competent cells in the absence of fetal bovine serum (FBS), which will enhance the clinical utility of this approach. Hematopoietic progenitor cells obtained from normal bone marrow and from leukapheresis products were studied. The mononuclear fraction was enriched for CD34 cells using the Ceprate CD34 biotin kit (CellPro #LC34-1 or LC34-2). The selected cells were expanded for two weeks in Iscove's medium supplemented with 20% FBS and various combinations of interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF) and interleukin-6 (IL-6) added either simultaneously or sequentially. The optimal combination of these factors identified for myeloid expansion was simultaneous addition of IL-3, SCF and G-CSF (at 50 ng/ml each), resulting in an average 773 ± 133-fold expansion of nucleated cells (n = 5). When corrected for the purity of CD34 cells in the starting population, the mean fold expansion with IL-3, SCF and G-CSF was 2,265 ± 729. A mean of 74.7 ± 10.5% (n = 3) of the expanded cells was positive for CD11b; 86-91% (n = 2) of the cells were promyelocytes or more mature granulocytes. Functional assays demonstrated normal phagocytosis and intracellular killing of Staphylococcus aureus (S. aureus) by the expanded cell population. Studies performed using cells expanded in defined serum-free media demonstrated that fold expansion was decreased and that the cells produced were less mature and functionally less competent than cells expanded with FBS. The decreased expansion could be partially reversed, and the functionality almost completely restored by the addition of autologous plasma.Keywords
This publication has 11 references indexed in Scilit:
- Regulation of Somatic-Cell Therapy and Gene Therapy by the Food and Drug AdministrationNew England Journal of Medicine, 1993
- Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietinBlood, 1993
- Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineageBlood, 1992
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992
- Studies of the Function and Structure of In Vitro Propagated Human GranulocytesPediatric Research, 1991
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid CancerNew England Journal of Medicine, 1991
- Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastomaBlood, 1991
- Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patientsBlood, 1991
- Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantationLeukemia Research, 1991
- Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients.Proceedings of the National Academy of Sciences, 1988